Neothetics reports disappointing study results

Neothetics Inc. (Nasdaq: NEOT) reported disappointing results from two Phase 3 trials of LIPO-202 to reduce central abdominal bulging due to subcutaneous fat sending the stock price plummeting $5.76 to $1.37.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.